1
                                  SCHEDULE 13G

                                 (RULE 13d-102)

 Information to be Included in Statements Filed Pursuant to Rule 13d-1(b), (c)
          and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2.



                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, DC 20549

                                  SCHEDULE 13G

                    Under the Securities Exchange Act of 1934
                          (Amendment No. ___________)*

                     Rockwell Medical Technologies, Inc.
- --------------------------------------------------------------------------------
                              (Name of Issuer)

                    Common Shares, no par value per share
- --------------------------------------------------------------------------------
                       (Title of Class of Securities)

                                 774374 10 2
- --------------------------------------------------------------------------------
                                 (CUSIP Number)

                               January 26, 1998
- --------------------------------------------------------------------------------

            (Date of Event Which Requires Filing of this Statement)

         Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:

                  [ ]    Rule 13d-1(b)

                  [ ]    Rule 13d-1(c)

                  [X]    Rule 13d-1(d)

         *The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter the disclosures provided in a prior cover page.

         The information required in the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act, but shall be subject to all other provisions of the Act (however, see
the Notes).


   2
                                                            

CUSIP NO.  774374 10 2                13G                 PAGE 2  OF 5 PAGES
- --------------------------------------------------------------------------------
  1     Names of Reporting Persons/I.R.S. Identification Nos. of Above Persons
        (Entities Only)
                             Michael J. Xirinachs
- --------------------------------------------------------------------------------
  2     Check the Appropriate Box if a Member of a Group     (a) [ ]
        (See Instructions)                                   (b) [X]

- --------------------------------------------------------------------------------
  3     SEC Use Only

- --------------------------------------------------------------------------------
  4     Citizenship or Place of Organization 

        United States of America
- --------------------------------------------------------------------------------
    Number of              
                           5       Sole Voting Power                          
      Shares                       770,000
                           -----------------------------------------------------
   Beneficially            6       Shared Voting Power                        
                                   0
     Owned by              -----------------------------------------------------
                           7       Sole Dispositive Power                     
       Each                        770,000
                           -----------------------------------------------------
     Reporting             8       Shared Dispositive Power                   

    Person With                    0
- --------------------------------------------------------------------------------
  9     Aggregate Amount Beneficially Owned by Each Reporting Person  
        770,000
- --------------------------------------------------------------------------------
 10     Check if the Aggregate Amount in Row (9) Excludes Certain Shares [ ]
        (See Instructions)

- --------------------------------------------------------------------------------
 11     Percent of Class Represented by Amount in Row (9) 
        15.9%
- --------------------------------------------------------------------------------
 12     Type of Reporting Person (See Instructions)
        IN
- --------------------------------------------------------------------------------


   3
CUSIP NO.  774374 10 2

ITEM 1.

         (a)      Name of Issuer:

                           Rockwell Medical Technologies, Inc.

         (b)      Address of Issuer's Principal Executive Offices:

                           28025 Oakland Oaks Drive
                           Wixom, Michigan  48393

ITEM 2.

         (a)      Name of Person Filing:

                           Michael J. Xirinachs

         (b)      Address of Principal Business Office or, if none, Residence:

                           28025 Oakland Oaks Drive
                           Wixom, Michigan  48393

         (c)      Citizenship:

                           United States of America


         (d)      Title of Class of Securities:

                           Common Shares, no par value per share

         (e)      CUSIP Number:

                           774374 10 2

ITEM 3.           IF THIS  STATEMENT IS FILED  PURSUANT TO  RULES 13D-1(B)  
                  OR 13D-2(B) OR (C),  CHECK  WHETHER THE FILING PERSON IS A:

                           Not Applicable

ITEM 4.           OWNERSHIP.

         Provide the following information regarding the aggregate number and
percentage of the class of securities of the issuer identified in Item 1.

         (a)      Amount beneficially owned:  770,000*




                               Page 3 of 5 pages
   4
CUSIP NO.  774374 10 2


         (b)      Percent of class:  15.9%*

         (c)      Number of Shares as to which the person has:

                  (i)      Sole power to vote or to direct the vote: 770,000*

                  (ii)     Shared power to vote or direct the vote:  0*

                  (iii)    Sole power to dispose or to direct the disposition 
                           of: 770,000*

                  (iv)     Shared power to dispose or to direct the disposition 
                           of:  0*

* 20,000 of the shares shown as beneficially owned by Michael J. Xirinachs are
shares that he may acquire within 60 days of December 31, 1998 upon exercise of
options granted to him by Rockwell Medical Technologies, Inc.

ITEM 5.           OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

         If this statement is being filed to report the fact that as of the date
hereof the reporting person has ceased to be the beneficial owner of more than
five percent of the class of securities, check the following |_|.

ITEM 6.           OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER 
                  PERSON.

                           Not applicable.

ITEM 7.           IDENTIFICATION  AND  CLASSIFICATION  OF THE SUBSIDIARY WHICH 
                  ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING 
                  COMPANY.

                           Not applicable.

ITEM 8.           IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

                           Not applicable.

ITEM 9.           NOTICE OF DISSOLUTION OF GROUP.

                           Not applicable.

ITEM 10.          CERTIFICATION.

                           Not applicable.



                               Page 4 of 5 pages
   5
CUSIP NO.  774374 10 2


                                    SIGNATURE

         After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.


Dated:  February 12, 1999                     /s/ Michael J. Xirinachs
                                              ----------------------------------
                                              Michael J. Xirinachs














                               Page 5 of 5 pages